Human apolipoprotein e isoforms differentially affect bone mass and turnover in vivo

Journal of Bone and Mineral Research

Volumn 28, Issue 2, 2013, Pages 236-245

  Dieckmann, Marco ^a   Timo Beil, F ^b   Mueller, Brigitte ^b   Bartelt, Alexander ^b   Marshall, Robert P ^b   Koehne, Till ^b   Amling, Michael ^b   Ruether, Wolfgang ^b   Cooper, Jackie A ^c   Humphries, Steve E ^c   Herz, Joachim ^a,d,e   Niemeier, Andreas ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Apolipoprotein E; bone mass; genetic risk factor; OPG; RANKL

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE MASS; BONE METABOLISM; BONE MINERALIZATION; BONE TURNOVER; CONTROLLED STUDY; CORTICAL THICKNESS (BONE); FEMUR; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HISTOLOGY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUMBAR VERTEBRA; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; NORMAL HUMAN; OSSIFICATION; OSTEOLYSIS; PHENOTYPE; PROTEIN EXPRESSION; TRABECULAR BONE;

ANIMALS; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; BIOMECHANICS; BONE AND BONES; BONE DENSITY; BONE REMODELING; FEMALE; FEMUR; GENE KNOCK-IN TECHNIQUES; HOMOZYGOTE; HUMANS; LUMBAR VERTEBRAE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; ORGAN SIZE; OSTEOGENESIS; OSTEOPROTEGERIN; PROTEIN ISOFORMS; RANK LIGAND;

EID: 84872445417     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1757     Document Type: Article

References (47)

1. Beisiegel U., Receptors for triglyceride-rich lipoproteins and their role in lipoprotein metabolism. Curr Opin Lipidol. 1995; 6: 117-22.
2. Herz J, Willnow TE., Lipoprotein and receptor interactions in vivo. Curr Opin Lipidol. 1995; 6: 97-103.
3. Mahley RW., Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988; 240: 622-30.
4. Plump AS, Breslow JL., Apolipoprotein E and the apolipoprotein E-deficient mouse. Annu Rev Nutr. 1995; 15: 495-518.
5. Heeren J, Beisiegel U, Grewal T., Apolipoprotein E recycling: implications for dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol. 2006; 26: 442-8.
6. Huang Y., Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases. Curr Opin Lipidol. 2010; 21: 337-45.
7. Mahley RW, Rall SC Jr., Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000; 1: 507-37.
8. Hauser PS, Narayanaswami V, Ryan RO., Apolipoprotein E: from lipid transport to neurobiology. Prog Lipid Res. 2011; 50: 62-74.
9. Heeren J, Grewal T, Laatsch A, Becker N, Rinninger F, Rye KA, Beisiegel U., Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation. J Biol Chem. 2004; 279: 55483-92.
10. Niemeier A, Schinke T, Heeren J, Amling M., The role of apolipoprotein E in bone metabolism. Bone. 2012; 50: 518-24.
11. Davignon J, Gregg RE, Sing CF., Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988; 8: 1-21.
12. Humphries SE, Talmud PJ, Hawe E, Bolla M, Day IN, Miller GJ., Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet. 2001; 358: 115-9.
13. Bartelt A, Beil FT, Schinke T, Roeser K, Ruether W, Heeren J, Niemeier A., Apolipoprotein E-dependent inverse regulation of vertebral bone and adipose tissue mass in C57Bl/6 mice: modulation by diet-induced obesity. Bone. 2010; 47: 736-45.
14. Nikolov IG, Joki N, Nguyen-Khoa T, Ivanovski O, Phan O, Lacour B, Drueke TB, Massy ZA, Dos Reis LM, Jorgetti V, Lafage-Proust MH., Chronic kidney disease bone and mineral disorder (CKD-MBD) in apolipoprotein E-deficient mice with chronic renal failure. Bone. 2010; 47: 156-63.
15. Schilling AF, Schinke T, Munch C, Gebauer M, Niemeier A, Priemel M, Streichert T, Rueger JM, Amling M., Increased bone formation in mice lacking apolipoprotein E. J Bone Miner Res. 2005; 20: 274-82.
16. Ghiselli G, Schaefer EJ, Gascon P, Brewer HB Jr., Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. Science. 1981; 214: 1239-41.
17. Schaefer EJ, Gregg RE, Ghiselli G, Forte TM, Ordovas JM, Zech LA, Brewer HB Jr., Familial apolipoprotein E deficiency. J Clin Invest. 1986; 78: 1206-19.
18. Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, Sullivan PM, Maeda N., Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest. 1999; 103: 1579-86.
19. Pendse AA, Arbones-Mainar JM, Johnson LA, Altenburg MK, Maeda N., Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. J Lipid Res. 2009; 50: 178-82.
20. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N., Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem. 1997; 272: 17972-80.
21. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N., Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest. 1998; 102: 130-5.
22. Amling M, Priemel M, Holzmann T, Chapin K, Rueger JM, Baron R, Demay MB., Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology. 1999; 140: 4982-7.
23. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR., Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595-610.
24. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R., Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25: 1468-86.
25. Roschger P, Paschalis EP, Fratzl P, Klaushofer K., Bone mineralization density distribution in health and disease. Bone. 2008; 42: 456-66.
26. Roschger P, Plenk H Jr, Klaushofer K, Eschberger J., A new scanning electron microscopy approach to the quantification of bone mineral distribution: backscattered electron image grey-levels correlated to calcium K alpha-line intensities. Scanning Microsc. 1995; 9: 75-86.
27. Seitz S, Koehne T, Ries C, De Novo Oliveira A, Barvencik F, Busse B, Eulenburg C, Schinke T, Puschel K, Rueger JM, Amling M, Pogoda P., Impaired bone mineralization accompanied by low vitamin D and secondary hyperparathyroidism in patients with femoral neck fracture. Osteoporos Int. Epub. 2012 May 12.
28. Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD., Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost. 1996; 75: 767-71.
29. Miller GJ, Bauer KA, Barzegar S, Foley AJ, Mitchell JP, Cooper JA, Rosenberg RD., The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost. 1995; 73: 82-6.
30. Bolla MK, Haddad L, Humphries SE, Winder AF, Day IN., High-throughput method for determination of apolipoprotein E genotypes with use of restriction digestion analysis by microplate array diagonal gel electrophoresis. Clin Chem. 1995; 41: 1599-604.
31. Shiraki M, Shiraki Y, Aoki C, Hosoi T, Inoue S, Kaneki M, Ouchi Y., Association of bone mineral density with apolipoprotein E phenotype. J Bone Miner Res. 1997; 12: 1438-45.
32. Saupe J, Shearer MJ, Kohlmeier M., Phylloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. Am J Clin Nutr. 1993; 58: 204-8.
33. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261: 921-3.
34. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ., Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA. 1994; 272: 1666-71.
35. Macdonald HM, McGuigan FE, Lanham-New SA, Fraser WD, Ralston SH, Reid DM., Vitamin K1 intake is associated with higher bone mineral density and reduced bone resorption in early postmenopausal Scottish women: no evidence of gene-nutrient interaction with apolipoprotein E polymorphisms. Am J Clin Nutr. 2008; 87: 1513-20.
36. Huang ZH, Maeda N, Mazzone T., Expression of the human apoE2 isoform in adipocytes: altered cellular processing and impaired adipocyte lipogenesis. J Lipid Res. 2011; 52: 1733-41.
37. Bour A, Grootendorst J, Vogel E, Kelche C, Dodart JC, Bales K, Moreau PH, Sullivan PM, Mathis C., Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks. Behav Brain Res. 2008; 193: 174-82.
38. Chen XH, Rodriguez S, Hawe E, Talmud PJ, Miller GJ, Underhill P, Humphries SE, Day IN., Evidence of admixture from haplotyping in an epidemiological study of UK Caucasian males: implications for association analyses. Hum Hered. 2004; 57: 142-55.
39. Caruso A, Motolese M, Iacovelli L, Caraci F, Copani A, Nicoletti F, Terstappen GC, Gaviraghi G, Caricasole A., Inhibition of the canonical Wnt signaling pathway by apolipoprotein E4 in PC12 cells. J Neurochem. 2006; 98: 364-71.
40. Zeleny M, Swertfeger DK, Weisgraber KH, Hui DY., Distinct apolipoprotein E isoform preference for inhibition of smooth muscle cell migration and proliferation. Biochemistry. 2002; 41: 11820-3.
41. Zhang KJ, Zhang HL, Zhang XM, Zheng XY, Quezada HC, Zhang D, Zhu J., Apolipoprotein E isoform-specific effects on cytokine and nitric oxide production from mouse Schwann cells after inflammatory stimulation. Neurosci Lett. 2011; 499: 175-80.
42. Niemeier A, Kassem M, Toedter K, Wendt D, Ruether W, Beisiegel U, Heeren J., Expression of LRP1 by human osteoblasts: a mechanism for the delivery of lipoproteins and vitamin K1 to bone. J Bone Miner Res. 2005; 20: 283-93.
43. Niemeier A, Niedzielska D, Secer R, Schilling A, Merkel M, Enrich C, Rensen PC, Heeren J., Uptake of postprandial lipoproteins into bone in vivo: impact on osteoblast function. Bone. 2008; 43: 230-7.
44. Huebbe P, Nebel A, Siegert S, Moehring J, Boesch-Saadatmandi C, Most E, Pallauf J, Egert S, Muller MJ, Schreiber S, Nothlings U, Rimbach G., APOE epsilon4 is associated with higher vitamin D levels in targeted replacement mice and humans. FASEB J. 2011; 25: 3262-70.
45. Burr DB., The contribution of the organic matrix to bone's material properties. Bone. 2002; 31: 8-11.
46. Fratzl P, Gupta HS, Paschalis EP, Roschger P., Structure and mechanical quality of the collagen-mineral nano-composite in bone. J Mater Chem. 2004; 14: 2115-23.
47. Hawkes CA, Sullivan PM, Hands S, Weller RO, Nicoll JA, Carare RO., Disruption of arterial perivascular drainage of amyloid-beta from the brains of mice expressing the human APOE epsilon4 allele. PLoS One. 2012; 7: e41636.